Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SAN DIEGO, Feb. 28, 2024 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks